A massive study of 61 million women finds Depo-Provera increases risk of meningioma by 140% as criminal enterprise Pfizer faces a tsunami of lawsuits.
For decades, Pfizer has marketed its injectable birth control Depo-Provera as a convenient, long-acting option for women. What few were told — and what new research now confirms — is that this hormone shot doubles the risk of developing brain tumors.
The latest study, published in JAMA Neurology by researchers from the Cleveland Clinic and Case Western Reserve University, examined over 61 million U.S. medical records spanning two decades. Among these, women who used Depo-Provera — formally known as depot medroxyprogesterone acetate (DMPA) — were found to have a 140% higher risk of developing meningioma, a slow-growing but potentially disabling brain tumor.
Pfizer gave over 13,000 women disabling brain tumors with their birth control injections used by 25% of women.
A MASSIVE study of 61 million women found Depo-Provera shots increases risk of meningioma by 143%.
Criminal enterprise Pfizer now faces a TSUNAMI of lawsuits. https://t.co/39uEjkAyEl pic.twitter.com/j3IRwyocDE
— Nicolas Hulscher, MPH (@NicHulscher) May 28, 2026
